Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-AP for Peripheral Nerve Continuity Diagnosis
NCT04026568Phase 3Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalfampridine in peripheral nerve injury (PNI), sponsored by Penn State Health Milton S. Hershey Medical Center. Started Aug 2021; status: terminated.
02
Drugs
dalfampridine
03
Conditions
peripheral nerve injury (PNI)
Beyond the preview
Go deeper on NCT04026568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026568.